Clinical Trial Detail

NCT ID NCT03554083
Title Vemurafenib, Cobimetinib, and Atezolizumab in Treating Participants With High-Risk Stage III Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

melanoma

Therapies

Atezolizumab + Cobimetinib

Atezolizumab + Cobimetinib + Vemurafenib

Age Groups: senior adult

No variant requirements are available.